QURE will manufacture the product. The US list price is $3.5M for a single treatment, which the companies hope will provide a functional cure for a lifetime.
Hemophilia B, in which patients produce an insufficient amount of of Factor IX, comprises about 15% of all hemophilia cases.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.